Clinically Actionable Intelligence
Translational™ provides pharmacogenomic reporting for germline mutations that affect traditional chemotherapy for a wide range of cancers.
Our solutions transform genetic test results into concise, actionable reports for physicians.
We are developing reporting for somatic mutations that affect the choice of targeted therapies for lung cancer, melanoma and colon cancer. Reporting solutions may also be developed for hematologic malignancies, inherited risk factors, and prostate, breast, gastrointestinal stromal, and ovarian cancers.